272BIO Ltd is a specialist biotechnology company which focuses on developing novel biological therapies for veterinary disease areas. 272BIO has an established in vitro laboratory which is based on The Pirbright Institute site, a world-renowned centre of expertise in veterinary disease management and therapy. Biotherapeutics can provide solutions for areas of health which are difficult to tackle with conventional medicines. Traditional Biotherapeutics are becoming more and more common in Human Health due to their selectivity, specificity and flexibility. The cost of development and production of typical monoclonal antibodies all but excludes biotherapeutics from Animal Health. Therapies developed using VHH antibodies retain the positive attributes of antibodies, but at a much lower production cost. This brings biological solutions within the reach of Veterinary Medicine.